Rapid Dose Therapeutics Inc. | Home | Canadian Pharma-Tech Company
IFRS 16 und die Auswirkungen auf den deutschen Aktienmarkt
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48%